Professor Jianlin Shi received his Bachelor degree from Nanjing University of Technology in 1983, and obtained his Ph.D degree in 1989 in Shanghai Institute of Ceramics, Chinese Academy of Sciences. He had been working on the processing science of advanced ceramics, sintering theory of advanced ceramics, inorganic nanostructured materials, and transparent ceramics from 1983 till 2005. Since 1998 till now, his recent research interest mainly include: synthesis of mesoporous materials and host-guest mesoporous nanocomposites; hierarchically micro-/mesoporous zeolite for large molecule- involved catalytic applications; mesoporous silica nanoparticles and related nanostructured nanocomposites for biomedical applications; Upconversion nanoparticles and related nanostructures for biomedical applications. Most recently, a novel research frontier of “nanocatalytic medicine” has been established in which non-toxic nanoparticles rather than conventional highly toxic chemodrugs were used to initiate intratumoral in-situ catalytic chemical reaction for antitumor purpose. More than 500 papers have been published, and the publications were cited by others for more than 33,000 times with an H-index of 108. He has been presented as highly cited researcher in 2015-2017 by Thomson Reuters. As the project leader and first awardee, he has been awarded, the National Nature Science Award (second class, 2011), Municipal Nature Science Award of Shanghai (first class, 2008 and 2014), and Municipal Scientific and Technological Progress Award (first class, 2009).

 Dr. Rui Vitorino works in the Department of Medical Sciences at the University of Aveiro, where he is the principal investigator. His expertise in OMICS, especially in proteomics and bioinformatics, makes him a pioneer in this field. Dr. Vitorino's research focuses on the detailed analysis of biofluids, such as saliva and urine, to decipher molecular pathways associated with different disease phenotypes. He employs a variety of multidisciplinary techniques for protein enrichment and biofluid analysis, all aimed at improving the detection and understanding of disease biomarkers. Since receiving his PhD in biochemistry in 2004, Dr. Vitorino has made significant contributions to proteomics. His innovative work has been instrumental in overcoming previous analytical challenges and potentially changing the landscape of early disease detection and risk assessment through the creation of comprehensive multimarker panels. His research spans a broad range of areas, including molecular and cell biology. His work is characterised by its thoroughness, from conducting detailed mechanistic studies to performing preliminary investigations and confirmatory studies, all underpinned by sound methodology and the addition of valuable data and insights that have the potential to influence future research. Dr. Vitorino’s academic track record is marked by over 240 publications, more than 7400 citations and an h-index of 38. He is involved in over 40 scientific projects, many of which are supported by the European Union and involve international collaborations. Dr. Vitorino is known for his expertise in the field of proteomics. He has collaborated with various research groups worldwide and has been instrumental in major projects such as the EU-ETN and COST Actions. His work is a testament not only to his deep knowledge of the field, but also to his commitment to promoting scientific understanding and collaboration.

 Prof. Yu, M.D., is a professor and doctoral supervisor at the School of Life Science and Technology, Beijing University of Chemical Technology, and an independent director of biomedical enterprises in the Association of Listed Companies. He has been engaged in clinical and scientific research management in hospitals, pharmaceutical enterprises and universities for more than thirty years. He has long-term practical experience in biopharmaceuticals and life science research, and has presided over the completion of more than twenty products that have been awarded new drug production certificates. He is responsible for completing a number of major national new drug special projects, scientific and technological research and other topics, published more than a hundred scientific research papers, published more than 20 academic monographs, won a number of provincial and ministerial awards, is now mainly engaged in life histology and big data interpretation, systems biology, Chinese medicine and health and other areas of research.

Dr. Yang has published over 70 papers across prestigious international journals including Cell Research, European Urology, Cancer Research, Clinical Cancer Research, Molecular Cancer, Journal of Experimental Medicine, Chemical Engineering Journal, EBioMedicine, and Critical Reviews in Food Science, with over 1000 citations. Additionally, he has published 8 professional books. He has led or participated in 14 projects funded by the Ministry of Science and Technology, the National Natural Science Foundation of China, and other national and local government agencies. Furthermore, he has applied for 23 Chinese invention patents with 12 granted. He has obtained the Shenzhen Science and Technology Progress Award (First Prize) in 2020 and the Outstanding Paper Award of Journal of Bioengineering in 2021.

Associate Professor of Pathology & Executive Physician, Bologna University, S. Orsola Malpighi Hospital, Bologna, Italy

Adjunct Professor of Hematology and Pathology at Jomo Kenyatta University of Agricolture and Technology, Nairobi, Kenya

Member of the Scientific Committee, Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy

National Academic Qualification as Full Professor of Pathology

Associate Editor for the American Journal of Blood Research, Modern Chemotherapy, World Journal of Hematology, Frontiers in Molecular Biosciences, Helyon.

Member of the SIE, SIES, ASH, AACR, SIAPEC/IAP, EHA, ELN/EWALL, FIL

Professor Ziad El Rassi matriculated to Claude-Bernard University in Lyon, France, for M.S. and Ph.D. degrees in analytical chemistry in 1974 and 1978, respectively. A visiting Assistant Professorship followed at Ecole Centrale de Lyon (Engineering School), France (1978-1980).  He then joined the Chemical Engineering Department at Yale University, New Haven, CT, as an Associate Research Scientist (1980-1985) and was appointed to Research Scientist over the period of 1985-1988.  An Assistant Professorship was accepted in 1988 at Oklahoma State University (OSU) in the Department of Chemistry.  He rose through the ranks to become Full professor in 1998.  In 2013, he got promoted to Regents Professor, which is considered the most prestigious rank that may be attained by faculty at Oklahoma State University. Prof. El Rassi is a member of the permanent scientific committees of The Asia Pacific International Symposium on Microscale Separations, The International Symposium on Capillary Electroseparation Techniques (ITP), and The Latin-American Symposium on Biotechnology, Biomedical, Biopharmaceutical and Industrial Applications of Capillary Electrophoresis and Microchip Technology

Prof. Yu received his undergraduate education at the Henan University of Traditional Chinese Medicine, and obtained his PhD degree in biochemistry from the Hong Kong University of Science and Technology. Before joining the Hong Kong Baptist University, Prof. Yu once worked at China Pharmaceutical University, Nagasaki University, Hong Kong University of Science and Technology, Xiamen University and University of Macau. Prof. Yu is known for his research in herbal pharmacology, and in processing of Chinese medicinal materials. He has published more than 200 peer-reviewed research papers.

Dr. Ahmed Mohammed Abu-Dief Mohammed, Lecturer of Inorganic and Physical Chemistry at Chemistry Department, Faculty of Science, Sohag University, Sohag, Egypt, Post doctor, Faculty of Chemistry, Oviedo University, Spain,2015. Dr. Ahmed Mohammed Abu-Dief publishes more than 65 articles in international journals, 7 books and participates in more than 53 workshops and international conferences. Moreover, Dr. Ahmed Mohammed Abu-Dief works as a reviewer in 87 international journals and member of editorial board in more than 25 journals.

Dr. Abdelazeem Mohamed Algammal works as a Professor Doctor and Head of Department of Bacteriology, Immunology, and Mycology, Suez Canal University, Egypt. He is an expert in the fields of Microbiology, Molecular biology, and Immunology. He had completed his Ph.D. in "Molecular typing of exotoxins genes in S. aureus isolates" in 2011. He is a certified Entrepreneurship trainer from the International Labour Organization and a trainee at the One Health Training Program at Duke Health Institute, Duke University, NC, USA (2019). He has been listed in the Stanford University (California, USA) Ranking of the World Scientists: "World's Top 2% Scientists". He has gained The University Encouragement and Appreciation Award, Suez Canal University, 2021 (Best Applied Research).

- Medical Doctor, University of TOURS, 1979

- Pharmaceutical Doctor, University of TOURS, 1970

- Degrees in Neuropsychopharmacology, Clinical pharmacology and General   Pharmacology, University of PARIS (1977-1978)

- Psychiatrist 1997 (National Committee of the French Medical Board)

- Psychiatrist presently in a centre for mental handicapped adults in Montredon (near Narbonne)

- Visiting Professor University of Craiova (Romania)

- WHO expert for drug dependence (2000-2016)

- Scientific secretary of Athens ‘congress of WFSBP 2015

- Professor of Pharmacology, University of Nantes, 1985-2012

- Psychiatrist at the Nantes academic hospital till 1997

- Adjunct Professor, Department of Psychiatry, University of Edmonton (Alberta) from 1995-2006 

- Head of Research: Neurobiology of anxiety and depression (University of Nantes) 1988-2009.

Professor Chen Jia-xu, MD, PhD, is native of Hubei, China. Professor Chen received his first degree in Chinese Medicine from the Hubei University of Traditional Chinese Medicine, and obtained his master’s and PhD degrees from Beijing University of Chinese Medicine (BUCM). He is a state approved doctoral supervisor, and director of state-level subject of Chinese Medicine Diagnosis in BUCM. He is one of the best-known and highly respected practitioners and teachers in BUCM with many years of professional experience. Dr. Chen has spent virtually his entire career at this prestigious university, where he has been teaching, conducting research, and practicing at the hospital since 1988. Professor Chen’s research interests focus on the standardization of Chinese medicine diagnosis, He has published more than 200 articles and obtained many awards in recent years. In 2004 his Diagnostics in Chinese Medicine was awarded as the National Elaborate Course from the Ministry of Education of China, and then was supported by the China National Funds for Distinguished Young Scientists in 2008.

Dr. William Cho is a biomedical scientist at the Department of Clinical Oncology, Queen Elizabeth Hospital in Hong Kong. With a strong background in cancer biomarker discovery and translational research, Dr. Cho has published extensively in peer-reviewed journals. His research interests include genomics, proteomics, and liquid biopsy in oncology. He actively serves on editorial boards and is a frequent reviewer for international scientific journals.

Prof. Dai’s research is focused on sophisticated biomaterials and nanomedicine for the development of advanced drug delivery systems, molecular imaging and sensing of diseased cells and organs. He has published over 200 scientific journal papers on peer-reviewed journals, and delivered over 100 plenary/keynote/invited talks on various conferences. He has developed a new ultrasound contrast agent. Phase I clinical trial has been completed and phase III clinical trial will be completed in 2023. He won two first prizes of Provincial and Ministerial Natural Science, and the P & G Teacher Award.

Full Professor, Dept. Biomedical Engineering
National Outstanding Young Scholar
Chairman, Contrast Enhanced Imaging Technology Branch of China Pharmaceutical Biotechnology Association
Chairman Designate, Nano Oncology Branch of China Anti Cancer Association

The European Association for Cancer Research (EACR) member, the British Association for Cancer Research (BACR) member and the UK Early Career Researchers in Cancer (UK ECRC) member. 2023 World top 2% scientists. 

Pedro Fonte is Assistant Professor at the Faculty of Sciences and Technology, University of Algarve, Portugal. He is also an integrated member at Center of Marine Sciences (CCMAR), University of Algarve, Portugal and collaborator researcher at the Institute for Bioengineering and Biosciences, Instituto Superior Técnico, University of Lisbon, Portugal. He graduated in Pharmaceutical Sciences in 2010 and obtained his PhD in Pharmaceutical Sciences – Nanotechnologies specialty at the Faculty of Pharmacy, University of Porto, Portugal in collaboration with the University of Copenhagen, Denmark, in 2016. He also obtained a Master of Business Administration (MBA) at the Faculty of Economics and Business Management, Lusíada University, Portugal in 2012. His area of scientific activity is on the development of new drug delivery systems by means of colloidal carriers, structural characterization of proteins entrapped into micro- and nanocarriers, lyophilization of biopharmaceuticals, targeted and controlled delivery of drugs across biological barriers, solid state characterization of pharmaceuticals and drying of pharmaceuticals and biopharmaceuticals. He is also conducting research in the regenerative medicine field, focusing in wound healing, tissue regeneration and cell therapy. In his activity he is enrolled in the up-scale of pharmaceutical products and is involved in entrepreneurship activities.

Prof. Ge graduated from Nanjing University of Traditional Chinese Medicine as a doctoral student, and postdoctoral fellowship in Chinese medicine at Hunan University of Traditional Chinese Medicine. He is a second-class professor of Integrative Medicine, a doctoral supervisor, a leader of the key discipline of Integrative Medicine Clinical (Cardio-Cerebral Diseases) of the State Administration of Traditional Chinese Medicine (SACTM), a leader of the key discipline of Integrative Medicine Fundamental in Hunan Province, a director of Hunan Key Laboratory of Integrative Prevention and Treatment of Cardio-Cerebral Diseases, a leader of the Natural Science Innovation Group of Hunan Province, and a candidate of the 121 Talent Project of the New Century in Hunan Province.

Dr Betti Giusti scientific activity has been dedicated to the comprehension of pathophysiologic mechanisms and molecular bases of atherosclerotic and thromboembolic diseases, and extracellular matrix disorders. Since her graduation she has been devoted to research on lympho-monocyte relationships, events associated to lymphocyte-induced monocyte activation, such as cytokine production and procoagulant activity, and role of different lymphocyte subpopulations during immune responses. Her current research interests include pathophysiology of thrombophilic states and clinical significance of hypercoagulability markers and, in particular, the role of inflammation and immune response in cardiovascular diseases. Part of her present activity is in the field of personalized medicine, and, in particular, in defining the molecular mechanisms of individual response to antiaggregant, anticoagulant, lipid lowering and antihypertensive therapies. In particular, as concerns the molecular mechanisms of residual platelet reactivity on antiaggregant therapy in high risk vascular patients she widely investigated the pharmacogenetics contribution. Moreover, her interest has been dedicated to the evaluation of molecular bases of multifactorial diseases in the field of cardiovascular disease by studying mutations/polymorphisms in candidate susceptibility genes. A further issue of research is represented by the study of the molecular bases of extracellular matrix diseases, such as Marfan syndrome, abdominal and thoracic aortic aneurysms, Bethlem myopathy and Ullrich scleroatonic muscular dystrophy.
Dr Betti Giusti scientific activity was documented by the presence as co-authors of 200 papers on peer reviewed journals (H-Index=45 scopus, 52 Google Scholar).

Prof. Grootveld is the author of 165 full, peer-refereed research publications in reputable international scientific and/or clinical journals, nearly 50 reviews/book chapters, 4 edited/authored books, and more than 250 refereed conference contributions. Since 1987, he has attracted £8M of external research funding, and to date his publications have had more than 10,000 Citations, with an h-index of 50, and an i10 index of 132 (Google Scholar Citations). 

Fellow of the Royal Society of Biology, the Royal Society of Chemistry, and the Institute of Biomedical Sciences.

Received the Second Prize of the National Science and Technology Progress Award, the Second Prize of the Chinese Medical Science and Technology Award, the Second Prize of the Jiangsu Provincial Science and Technology Award, the Third Prize of the Beijing Science and Technology Progress Award, and others.

Honored with titles such as Outstanding Young Teacher by the Ministry of Education, National Candidate of the New Century Hundred, Thousand, and Ten Thousand Talents Project, Expert Receiving the State Council Special Government Allowance, and Young and Middle-Aged Expert with Outstanding Contributions by the Ministry of Health.

Shareholder & Owner, Innovation Center for Advanced Technology, Matrix HT, Inc. New York, USA

Dr. Hai-Feng (Frank) Ji is a professor in the Department of Chemistry at Drexel University. In addition, Professor Ji is an affiliated faculty member of the College of Engineering's Department of Materials Science and Engineering. Professor Ji’s research interests focus on drug discovery, polymer chemistry, hydrogels, plasma chemistry, MEMS devices, nanomaterials for energy and environmental applications, nanopillars and phosphorus-based nanomaterials for energy applications, and surface chemistry. He is a co-author of more than 215 peer-viewed journal articles and book chapters. He has an H-index of more than 43.

Dr. Muhammad Kabir completed his PhD in Computer Science and Technology at the School of Computer Science and Engineering, Nanjing University of Science and Technology (NJUST), Nanjing, China. He previously served as an Assistant Professor at the School of Systems and Technology – Department of Computer Science, University of Management and Technology (UMT), Lahore, Pakistan, for 2.5 years. Currently, he is working as a researcher in the Protein Structure and Bioinformatics Group at the Biomedical Center (BMC), Lund University, Sweden. Dr. Kabir is enthusiastic about engaging in a stimulating research environment, with a focus on enhancing his existing expertise and acquiring new skills to stay at the forefront of the evolving field of bioinformatics. In his current postdoctoral research, he is dedicated to advancing machine learning methods designed for the identification and classification of disease-causing genetic variations, with the ultimate aim of contributing to both scientific research and clinical practice.

• Special interests in clinical genetics include genetic diseases of children, rare genetic disorders, inherited conditions of heart and blood vessels, genomic and precision medicine and genomic applications in healthcare.
• Author/Editor of several genetic/genomic books and journals.
• Founder-Chair of the Global Consortium for Genomic Education (GC4GE), Global Familial Heart Challenge (GFHC), and UK India Genomic Medicine Alliance (UKIGMA).

Dr. Lane Hsien-Yuan specializes in the treatment of schizophrenia, bipolar disorder, depression, and dementia. His team is dedicated to discovering safer natural compounds for the treatment of psychiatric disorders and has received prestigious national and international awards for their work. 

Director, Addiction and Mental Health Research Center, China Medical University Hospital
Attending Physician, Department of Psychiatry, China Medical University Hospital
Former Chief, Department of Psychiatry, China Medical University Hospital
Former Director, Community Psychiatry, China Medical University Hospital
Former Director, Addiction Medicine Research Center, China Medical University Hospital
Former Director, Institute of Medicine, China Medical University
Professor and Former Director, Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University
President, Taiwan Schizophrenia Research Society
Chair, Education Committee, Taiwanese Society of Psychiatry
Professor and Director, Graduate Institute of Biomedical Sciences, China Medical University
Director, Department of Psychiatry, School of Medicine, China Medical University
Fellow, International College of Neuropsychopharmacology (CINP)
International Advisory Board Member, Asian College of Neuropsychopharmacology (AsCNP)

Dr. Lifeng Lin is an Associate Professor in the Department of Epidemiology and Biostatistics at the University of Arizona, with a courtesy appointment in the Statistics and Data Science Graduate Interdisciplinary Program. His research focuses on developing and disseminating advanced statistical methodologies to enhance the validity, transparency, and robustness of evidence synthesis. His methodological expertise spans meta-analysis, network meta-analysis, Bayesian methods, multivariate modeling, fragility analysis, and the assessment of publication bias. In addition, Dr. Lin has made substantial contributions to biomedical research through collaborative applied statistical work in areas such as aging, mental health, and women’s health. His research has been supported by grants from the U.S. National Institutes of Health and the Arizona Biomedical Research Centre.

Giuseppe Murdaca has received his PhD in Science and Space Engineering at the University of Genova (Italy) during the period of 2000-2003. Currently, he is working as Assistant professor in Internal Medicine University of Genova (Italy).

His research has included Immunodeficiency Autoimmunity Neuro-endocrino-immunology Pharmacogenomics.

Based on this research and fellowship training he has received several awards and honors, such as:
Prize for young researchers of the study, assigned by the GILS, with the following motivation: "Standardization of a method to assess impairment by skinfold thickness skin", delivered on the occasion of the "Day VII Italian to fight Scleroderma" (Milan, 17/3 / 2001).

Award for one of the three best oral presentations at the Ninth Congress of the Inter-SIMI Piemonte and Valle D'Aosta, Liguria (Genoa, 06.17.2004): Murdaca G., Fenoglio D., M. Setti, Brenci S., Villa R., Pontali E., A. Kunkl, Indiveri F., Puppo F. "Generation of CD4 + lines specific for Pneumocystis carinii and Candida albicans obtained from HIV + patients. Meaning of the coexpression of IFN-? and IL-4 ".

• FEBS bursary for attending the 34th FEBS Congress in Prague, Czech Republic
• FEBS bursary for attending the 35th FEBS Congress in Gothenburg, Sweden
• EACR Travel Fellowship
• FEBS Collaborative Experimental Scholarships for Central & Eastern Europe
• Croatian Science Foundation’s Fellowship for Doctoral Students (project number 03.01/214)

Dr. Saturnino Carmela is a distinguished academic and researcher in the field of pharmaceutical sciences. She earned both her undergraduate degree in Pharmacy and her postgraduate degree in Pharmaceutical Chemistry from the University of Naples, where she later completed her Ph.D. in Pharmaceutical Sciences. Throughout her academic journey, Dr. Carmela was the recipient of numerous scholarships in recognition of her outstanding research contributions.

Currently, she serves as a Professor in the Department of Sciences and Medicinal Chemistry at the University of Basilicata. Her research interests lie in pharmaceutical chemistry and drug development, and she has published extensively in several high-impact, peer-reviewed journals.

Dr. Carmela is an active member of various international scientific societies and regularly participates in global conferences, contributing her insights and staying abreast of the latest developments in her field. Her dedication to advancing pharmaceutical research and education has made her a respected figure among her peers and a mentor to aspiring scientists.

Chief of the Anatomic Pathology Division at the Children’s Hospital of Eastern Ontario

Professor of Pediatrics and Pathology, University of Alberta and Ottawa, Canada

Consultant of Carcinogenesis in Experimental Animals at the WHO/IARC, Lyon, France

“ad-hoc” Peer-Referee for the National Toxicology Program, NIH, USA

Editor-in-Chief and in the Editorial Board of Prestigious Medical Journals and international agencies

After postdoctoral training in molecular immunology from Weill Medical College of Cornell University, Dr. Shen spent seven years at MIT Center for Cancer Research and Department of Biology as a research scientist for high throughput technology and computational method development. Prior to joining IHI at UMN, Dr. Shen worked at Boston University Medical School as an assistant professor for two years and NYU Langone Medical Center as an associate professor for six years for teaching and research at the area of genomics and bioinformatics. From 2007 to 2008, Dr. Shen also spent two years at Helicos Bioscience for the next generation sequencing technology development. Dr. Shen completed undergraduate and graduate education from Nantong Medical College and Suzhou Medical College, respectively in China.

Dr. Neeraj S. Thakur is a research scientist and project lead at the Hough Ear Institute in Oklahoma City, focusing on inner ear research. With a Master’s and Ph.D. in Pharmaceutical Technology (Biotechnology) from the National Institute of Pharmaceutical Education and Research (Mohali, India), he specializes in neurotheranostics, synthetic chemistry, cellular biology, and histology. His research involves advanced formulation development and testing, particularly in drug delivery systems for hearing-related applications. Thakur has an impressive track record of 29 peer-reviewed publications, 5 patents, 1 book, and 6 book chapters, with expertise in nanotechnology, drug delivery platforms, and biomedical research. His work spans international research institutions, including postdoctoral positions at the University of Oklahoma Health Sciences(Oklahoma City), the University of Geneva (Switzerland), and the Center of Innovative and Applied Bioprocessing (CIAB, India), and continues to push boundaries in pharmaceutical and biomedical innovations as a member of the HEI Research Team.

Dr. Pavlos Zarogoulidis, M.D, Ph. D Director of Pulmonary Department, ``General Clinic Euromedica`` Private Hospital, Thessaloniki, Greece have three MS.c in ``Clinical Pharmacology``, ``Sleep Medicine`` and  ``Thyroid Gland Disease and Treatment ``and my Ph. D is regarding inhaled chemotherapy for lung cancer. In my everyday practice I perform diagnosis for lung cancer with bronchoscopy, radial and convex probe endobronchial ultrasound and medical thoracoscopy. 

Sugandh comes from the Institute of Life Sciences (ILS), India where he worked on miRNAs-based biomarker development of Head and Neck Cancer.  Currently, he is focusing on the development of skin disease biomarkers based on multi-omics data such as scRNA Seq, CITE Seq, and SNPs using machine learning with deep learning. 

Dr. Yan Tong-Meng obtained his Bachelor and PhD degrees in medicine from Southern Medical University (the former First Military Medical University) in 2010 and 2015, respectively. He has been in the College of Pharmacy, University of Houston, USA, as a visiting scholar carrying out the proteome research in hepatocellular carcinoma patients from February to August, 2013. After graduation, he joined State Key Laboratory for Quality
Research in Chinese Medicines, Macau University of Science and Technology (MUST) for his postdoctoral training, and was promoted to be an assistant professor in 2022. Dr. Yan’s research areas include bioanalytical chemistry, chemical biology and proteomics. His research mainly focuses on the functional roles of RNA epigenetics in cancer, proteomics and metabolomics profiling of cancer, and TCM-based new drug discovery and development. He has published research papers in Nucleic Acids Research, Analytical Chemistry，Molecular Therapy-Nucleic Acids，Molecular Cancer Therapeutics, and Pharmaceutical Research. He also obtained 7 international patent approvals and these IP of TCM siRNA new drug technology have been successfully transferred.